Search PubMed⌕ Search

Biomedical subjects

S Dische

Publications and source records attributed to S Dische.

At least 145 records · Page 8Linked to original sources
PubMed1981

Radiation myelopathy in patients treated for carcinoma of bronchus using a six fraction regime of radiotherapy.

The adoption of a six-fraction regime of radiotherapy for patients with locally advanced carcinoma of the bronchus was followed by the appearance of radiation myelitis in eight cases. These were among a group of 130 patients given radiotherapy with anterior and posterior treatment fields, without shielding of the spinal cord. Radiation myelitis was found only in those where the calculated spinal-cord dose exceeded 3350 cGy (rad). The possible precipitating factors in the eight patients who suffered myelopathy were compared with those in the remaining 62 patients who also received spinal-cord doses calculated to be greater than 3350 cGy (rad). Only one difference was found--the haemoglobin concentration was significantly higher in those who suffered neuropathy compared with those who did not (P = 0.05).

Aged↗
PubMed1980

Tumour regression as a guide to prognosis: a clinical study.

The response seen at the end of a course of radiotherapy in 116 patients with advanced carcinoma of the cervix included in hyperbaric oxygen trials was assessed by reduction in bulk and by histological examination. These patients have now been carefully followed for a minimum of three and a maximum of 13 years. The degree of regression, three and a maximum of 13 years. The degree of regression, as measured by reduction in bulk at the primary site, was as measured by reduction in bulk at the primary site, was found to predict closely the subsequent local tumour failure, survival and freedom from metastasis. The histological assessment also could be associated with the subsequent course, but the correlation was much weaker. In a trial of hyperbaric oxygen, where radiotherapy was given in 27 fractions to both groups, the immediate response was significantly better in the patients treated in oxygen, so predicting the result of the trial seen in long-term follow up. In the radiotherapy of carcinoma of cervix, reduction in bulk of the primary tumour at the end of treatment is a valuable prognostic index.

Female↗
PubMed1980

Tumour regression and prognosis: a clinical study.

In advanced carcinoma of the uterine cervix reduction in the size of the tumour at the end of external beam radiotherapy closely correlated with subsequent local tumour control, freedom from metastasis and survival. A histological assessment of response showed a weaker correlation with subsequent events. In carcinoma of the bronchus the reduction in bulk of tumour assessed radiologically and the disappearance of tumour cells from the sputum did not correlate with the duration of survival. In the observation of tumour response the considerable differences which must be expected when comparing different tumours should not detract from the current and potential value of such studies.

Bronchial Neoplasms↗
PubMed1980

Misonidazole in the clinic at Mount Vernon.

Clinical experience at Mount Vernon from November 1974 has now extended to over 200 patients. Neurotoxicity is the dominant dose-limiting toxic effect and was seen in 28% of those given two or more doses. Randomized clinical trials in carcinoma of bronchus, bladder, and breast have so far shown no advantage to those in patients with carcinoma of the cervix. Although misonidazole may be shown to be of benefit in certain situations, it is unlikely to be a drug of general use in radiotherapy. The promise of an increase in local tumor control in radiotherapy with use of an effective hypoxic cell sensitizer remains. New more effective hypoxic cell sensitizers are needed.

Adult↗
PubMed1978

Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervix.

In a randomized controlled clinical trial of hyperbaric oxygen in the radiotherapy of advanced carcinoma of the uterine cervix a total of 320 cases were contributed by four radiotherapy centres in the United Kingdom. The use of hyperbaric oxygen resulted in improved local control and survival. The benefit was greatest in patients under the age of 55 who presented with stage III disease. There was a slight increase in radiation morbidity but it seemed that the benefit of hyperbaric oxygen outweighed this increase in morbidity and that there was a true improvement in the therapeutic ratio.

Adult↗
PubMed1978

Hyperbaric oxygen: the Medical Research Council trials and their clinical significance.

The clinical trials of the use of hyperbaric oxygen in radiotherapy conducted by the Medical Research Council's working party have shown that local cure and survival can be improved in head and neck and cervical cancer. Evidence for benefit has been presented in carcinoma of bronchus, but none has so far been found in carcinoma of the bladder. Although hyperbaric oxygen has produced increased effect upon normal tissues as well as upon tumour, a real improvement in therapeutic ratio appears to be present. The future use of hyperbaric oxygen in radiotherapy will depend upon a comparison of effectiveness with other methods now being tested to improve radiotherapy. The trials have yielded much fundamental and clinical data of general relevance in the radiotherapy of malignant disease.

Bronchial Neoplasms↗
PubMed1978

The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.

Misonidazole has been given to a total of 87 patients. Neurotoxicity has occurred--convulsions with the higher doses and peripheral neuropathy with the lowern ones. The data from 34 patients receiving 4--7 doses has been analysed. Peripheral neuropathy is related to the total tissue exposure. By monitoring serum levels and controlling the total dose given, convulsions are avoidable and peripheral neuropathy restricted to a low and acceptable level.

Drug Administration Schedule↗
PubMed1978

The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.

The amount of misonidazole which may be given to one patient is limited because of the risk of neurotoxicity. The drug may be given with every treatment of a multi-fraction course of radiotherapy or only with some of the treatments. The number of radiotherapy treatments can be reduced or multiple treatments given after each dose of the drug. Experience in 19 patients given daily doses of misonidazole is reported. This is practical regime to be considered for clinical trials of this hypoxic cell sensitizer.

Drug Administration Schedule↗
PubMed1978

Clinical experience with misonidazole.

A total of 62 patients with advanced tumours have now been treated by a fractionated course of radiotherapy, with misonidazole. The prime purpose of the administration of the drug to these patients was to determine safe dosage and suitable regimes for use in clinical radiotherapy. The reaction of normal tissues did not seem enhanced but there was an impression of increased tumour response.

Digestive System↗
PubMed1977

Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.

The hypoxic cell radiosensitizer, Ro 07-0582, has now been given in multiple doses to 16 patients. They have received a total of 15-51 g in 3-20 doses. Immediate tolerance was good, and satisfactory plasma levels of the drug were consistently obtained. Neurotoxicity was, however, troublesome: convulsions occurred in the patient given the highest dose, and there was peripheral neuropathy in 11 cases. Tumour concentrations similar to those in plasma were obtained in human tumours, in contrast to the findings in mouse tumours where concentrations are usually below 40% of plasma levels. In the treatment of human tumours, a lower dose of Ro 07-0582 should give useful hypoxic cell sensitization. Although the total dose of Ro 07-0582 must be limited, there is a real prospect that it will give benefit in clinical radiotherapy.

Adult↗